All terms in BMONT

Label Id Description
skin disease DOID_37 [An integumentary system disease that is located_in skin.]
excessive daytime sleepiness measurement EFO_0007875 [quantification of excessive daytime sleepiness such as how often it occurs and its severity]
Huntington's disease DOID_12858 [A neurodegenerative disease that has_material_basis_in autosomal dominant inheritance and is characterized by unwanted choreatic movements, behavioral and psychiatric disturbances and dementia and has_material_basis_in expansion of CAG triplet repeats (glutamine) resulting in neuron degeneration affecting muscle coordination, cognitive abilities.]
neurodegenerative disease MONDO_0005559 [A disorder of the central nervous system characterized by gradual and progressive loss of neural tissue and neurologic function.]
Alzheimer disease MONDO_0004975 [A progressive, neurodegenerative disease characterized by loss of function and death of nerve cells in several areas of the brain leading to loss of cognitive function such as memory and language.]
vascular endothelial growth factor EFO_0003276 [Vascular endothelial growth factor (VEGF) is a signal protein produced by cells that stimulates vasculogenesis and angiogenesis. It is part of the system that restores the oxygen supply to tissues when blood circulation is inadequate. Serum concentration of VEGF is high in bronchial asthma and low in diabetes mellitus. VEGF's normal function is to create new blood vessels during embryonic development, new blood vessels after injury, muscle following exercise, and new vessels (collateral circulation) to bypass blocked vessels. When VEGF is overexpressed, it can contribute to disease. Solid cancers cannot grow beyond a limited size without an adequate blood supply; cancers that can express VEGF are able to grow and metastasize. Overexpression of VEGF can cause vascular disease in the retina of the eye and other parts of the body. Drugs such as bevacizumab can inhibit VEGF and control or slow those diseases. VEGF is a sub-family of growth factors, to be specific, the platelet-derived growth factor family of cystine-knot growth factors. They are important signaling proteins involved in both vasculogenesis (the de novo formation of the embryonic circulatory system) and angiogenesis (the growth of blood vessels from pre-existing vasculature).]
oxygen saturation CMO_0001324 [The amount of oxygen bound to hemoglobin in the blood expressed as a percentage of the maximal binding capacity.]
insomnia measurement EFO_0007876 [quantification of insomnia such as how often it occurs and its severity]
enzyme-linked immunosorbent assay OBI_0000661 [An analyte assay where binding of an enzyme linked antibody to a material entity that is immobilized on solid support is detected utilizing a chemiluminescent reaction. Depending on the setup, the enzyme-linked antibody could be binding directly to the analyte, or it serves as a secondary antibody detecting binding of the primary antibody to the analyte.]
assay OBI_0000070 [A planned process with the objective to produce information about the material entity that is the evaluant, by physically examining it or its proxies.]
KLRB1 OMIT_0033136
Abnormality of movement HP_0100022 [An abnormality of movement with a neurological basis characterized by changes in coordination and speed of voluntary movements.]
history BFO_0000182
mosaic loss of chromosome Y measurement EFO_0007783
systolic blood pressure EFO_0006335 [The blood pressure during the contraction of the left ventricle of the heart.]
EC 1.1.1.34/EC 1.1.1.88 (hydroxymethylglutaryl-CoA reductase) inhibitor CHEBI_35664 [Any EC 1.1.1.* (oxidoreductase acting on donor CH-OH group, NAD(+) or NADP(+) acceptor) inhibitor that inhibits HMG-CoA reductases. Hydroxymethylglutaryl-CoA reductase inhibitors have been shown to lower directly cholesterol synthesis. The Enzyme Commission designation is EC 1.1.1.34 for the NADPH-dependent enzyme and EC 1.1.1.88 for an NADH-dependent enzyme.]
creatinine clearance CMO_0000765 [The clearance rate of creatinine, that is, the volume of plasma that is cleared of creatinine by the kidneys per unit time. Creatinine clearance is calculated using the level of creatinine in a sample of urine, usually one collected over a period of 24 hours, the corresponding plasma creatinine level, and the volume of urine excreted. It is used as an approximation of the glomerular filtration rate (GFR).]
cellular tumor antigen p53 PR_000003035 [A protein that is a translation product of the human TP53 gene or a 1:1 ortholog thereof.]
liver cirrhosis DOID_5082
Predictor NCIT_C75944 [Information or variable that supports a probabilistic estimate of future events.]